KAYS (Kaya Holdings) Moat Score: 2/10 (As of Jul. 02, 2026)


What is Kaya Holdings Moat Score?

Kaya Holdings KAYS Moat Score is 2 as of Jul. 02, 2026. The stock has 4 warning signs investors should review. Among 1,032 Drug Manufacturers companies, Kaya Holdings ranks better than 81.69% on this metric.

Kaya Holdings has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

Kaya Holdings has No Moat: Kaya Holdings Inc does not exhibit market leadership or significant customer switching costs. The company lacks valuable intellectual property, strong brand strength, and durable cost advantages. There are no significant regulatory barriers or exclusive licenses, and its innovation capabilities are not sufficient to establish a competitive edge.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Kaya Holdings might have No Moat - Very weak/transient advantages.

Kaya Holdings  (OTCPK:KAYS) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Kaya Holdings Moat Score Related Terms

KAYS vs APUS, IGPK, BIOE: Moat Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Kaya Holdings's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kaya Holdings Moat Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kaya Holdings's Moat Score distribution charts can be found below:

* The bar in red indicates where Kaya Holdings's Moat Score falls into.


Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
Kaya Holdings (KAYS) has a Moat Score of 2 as of Jul. 02, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Kaya Holdings ranks #189 out of 1032 companies in the Drug Manufacturers industry, placing it in the top 18.3%.
Is Kaya Holdings' Moat Score too high?
Kaya Holdings' current Moat Score is 2. Based on the distribution chart, Kaya Holdings ranks #189 out of 1032 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does Kaya Holdings' Moat Score compare to APUS and IGPK?
According to the Drug Manufacturers industry distribution chart, Kaya Holdings ranks #189 out of 1032 companies for Moat Score. This places Kaya Holdings in the top 18% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Drug Manufacturers company?
A good Moat Score depends on the Drug Manufacturers industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Kaya Holdings's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kaya Holdings stock overvalued right now?
Kaya Holdings (KAYS) has a current Moat Score of 2. The current Moat Score is 2. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Kaya Holdings (KAYS), the current Moat Score is 2 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kaya Holdings Business Description

Address 21218 St. Andrews Boulevard, Suite 300, Boca Raton, FL, USA, 33433
Kaya Holdings Inc is a holding company. It is focusing on wellness and mental health through operations in psychedelic treatment clinics, medical and recreational cannabis, and CBD products. The company own and operate a medical cannabis dispensary in the United States. Its has produced, distributed, and/or sold a full range of premium cannabis products including flower, oils, vape cartridges and cannabis infused confections, baked goods and beverages through a fully integrated group of subsidiaries and companies supporting distinctive brands.